Hochschulschrift
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
56 Blätter
- Sprache
-
Englisch
- Anmerkungen
-
Illustrationen
Universität Duisburg-Essen, Dissertation, 2023
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.03.2025, 11:45 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Entstanden
- 2022
Ähnliche Objekte (12)
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Apoptoseinduktion durch BRAF, MEK Inhibition in humanen Melanomzellen
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients